GSK (GSK.L) expects to deliver annual sales and profit growth towards the top end of its forecasts after beating ...

Blenrep approved in the EU for multiple myeloma | Regulatory NewsThe approval is based on superior efficacy results demonstrated by Blenrep combinations in the pivotal DREAMM-7 and DREAMM-8 phase ...

The FTSE 100 has continued to notch fresh highs, as UK stocks have been swept in broader market optimism around developments on US tariffs.

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

The FTSE 100 has ticked up this morning after what became a wobbly session on Monday, with a stack of fresh earnings updates helping traders early on Tuesday. Entain and Games Workshop are leading ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...